Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-HERO: Ultra-hypofractionated Radiotherapy plus Relugolix for Intermediate-risk Prostate Cancer
2024-518388-37-00Phase 2Authorised
- Sponsor
- Fondazione Radioterapia Oncologica
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tissue-plasminogen activator in prostate cancer (PCa), sponsored by Fondazione Radioterapia Oncologica. Primary endpoint: Complete biochemical response at 6 months. Planned start Apr 2025; status: authorised.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-518388-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518388-37-00.